Current Report · Items 3.01, 9.01 · 8-K

Bio Green Med Solution, Inc.

BGMSNASDAQEQUITYCurrent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 9.01. Financial Statements and Exhibits. Exhibit Exhibit No. 104 Cover Page Interactive Data File (embedded within the XBRL document)

Filed Nov 4, 2026Accepted Nov 4, 2026, 5:28 PM ESTCIK 1130166Accession 0001493152-26-049999

View company →Permanent SEC source ↗

Company context

We are a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival.

Current securities

BGMSNASDAQ · EQUITY · Current BGMSPOTC · PREFERRED · Current

Historical securities (2)

BGMSPNASDAQ · PREFERRED · Historical · closed Mar 20, 2026 CYCCOTC · EQUITY · Historical · closed Sep 11, 2025

Recent company filings

Registered securities in this filing

Bio Green Med Solution, Inc. · 8-K · Filed 2026-11-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol: BGMS
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-10-29

Dimensions: Not supplied

Accession 000149315226049999 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 9.01Item 9.01 - Financial Statements and Exhibits